PMHNP Scope of Practice for Anxiety in New York

If you’re a psychiatrist or PMHNP treating anxiety via telehealth, you know the clinical work is straightforward — but the regulatory landscape? That’s where it gets messy. Between federal DEA rules that keep getting extended, state-by-state prescribing laws, and the alphabet soup of licensing requirements, staying compliant while actually helping anxious patients can feel overwhelming.

Here’s what you actually need to know about treating anxiety disorders via telehealth in 2026, broken down by what matters for your practice.

The Federal Layer: DEA Rules on Controlled Substances

Let’s start with the good news: as of February 2026, you can still prescribe controlled anxiety medications via telehealth without an in-person exam. The DEA extended COVID-era flexibilities through December 31, 2025, and indications are this will continue while they work on ‘a new path forward for telemedicine.’

What this means practically: You can initiate benzodiazepines (alprazolam, clonazepam, lorazepam) for a new anxiety patient you’ve only seen via video visit. Before 2020, the Ryan Haight Act would have required at least one in-person evaluation first. That barrier is temporarily lifted.

The catch: This is temporary. The DEA proposed new rules in 2023 that would have reinstated in-person requirements (with a 30-day tele-prescribing allowance). After 38,000 public comments — many from mental health providers pointing out this would devastate access to care — they postponed implementation. But it’s coming eventually.

What you should do: Document your telehealth exams thoroughly. Conduct proper mental status evaluations via video (not just phone calls when possible). Be prepared for potential hybrid models in the future — some providers are already establishing relationships with local clinics for backup in-person visits if regulations change.

The reality check: Most first-line anxiety medications (SSRIs, SNRIs, buspirone, hydroxyzine) aren’t controlled substances anyway. The DEA rules mainly affect benzodiazepines and, for some providers, stimulants for comorbid ADHD. But benzos remain a common tool for acute anxiety management, so these rules matter.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State Licensing: The Non-Negotiable First Step

Before worrying about prescribing rules, you need the right license. You must be licensed in the state where your patient is physically located during the telehealth visit. Period. No exceptions, no shortcuts.

This gets expensive fast if you want to practice in multiple states. A California license costs $870. Texas? $788. New York? $735. If you’re trying to cover six states, you’re looking at $4,000+ just in licensing fees, plus the administrative headache of tracking multiple renewal dates and CE requirements.

Two potential helpers:

• Interstate Medical Licensure Compact (IMLC) for physicians: If you hold a license in an IMLC state, you can use an expedited process to get licenses in other IMLC states. Texas, Florida, Pennsylvania, and Illinois participate. California and New York do not.
• Nurse Licensure Compact for APRNs: More limited. The RN compact helps, but APRN practice authority is still state-specific.

Florida’s unique option: Florida offers a telehealth registration for out-of-state providers. Instead of getting a full Florida license, you can register to provide telehealth services to Florida patients. Requirements include active license in your home state, no discipline history, and malpractice insurance. Over 1,200 providers use this pathway.

Psychiatrists vs. PMHNPs: Scope Differences That Actually Matter

For Psychiatrists (MD/DO)

Your scope is straightforward: full independent practice authority in every state. No supervision, no collaborative agreements, no formulary restrictions for anxiety treatment. If it’s a legitimate medical use and you have the appropriate licenses, you can prescribe it.

Your regulatory checklist:

1. State medical license where patient is located
2. DEA registration
3. State-specific controlled substance license if required (Illinois, Florida, etc.)
4. PDMP registration and compliance with checking requirements
5. E-prescribing capability (mandatory in most states for controlled substances)

The real challenges are administrative — keeping up with PDMP rules that vary by state, documentation standards, and the volume of regulations, not restrictions on what you can do clinically.

For PMHNPs

Your life is more complicated because scope of practice varies dramatically by state. You can diagnose and treat anxiety everywhere, but whether you need physician oversight and what you can prescribe depends entirely on where your patient sits.

Full Practice Authority States (for experienced NPs):

• Illinois: 4,000 hours of experience + additional training gets you full practice authority, including independent prescribing of Schedule II-V
• New York: 3,600 hours under physician collaboration → then full independence (permanent as of 2022)
• California: Transitioning. As of 2023, experienced NPs can practice independently in certain settings. By 2026, full independence available for qualified NPs across all settings

Restricted Practice States (physician collaboration required):

• Texas: Prescriptive Authority Agreement with a physician required. Critical restriction: APRNs cannot prescribe Schedule II controlled substances in outpatient settings (only in hospitals or hospice)
• Florida: Written supervisory protocol with a physician required. One physician can supervise max 4 NPs
• Pennsylvania: Collaborative agreement required. Physician can collaborate with up to 4 NPs

Real-world impact: If you’re a PMHNP working with a platform like Klarity Health, you need physician collaborators lined up in Texas, Florida, and Pennsylvania. In New York and Illinois (if you’re experienced), you can operate independently. The platform’s compliance infrastructure has to handle this state-by-state.

The Schedule II Problem for NPs

Here’s where it gets specific: Texas doesn’t allow NPs to prescribe Schedule II controlled substances in outpatient settings. Period. The only exceptions are hospital inpatients, emergency departments, or hospice/palliative care.

For anxiety treatment, this mainly affects comorbid conditions. Schedule II includes stimulants (Adderall, Vyvanse) that might be needed for patients with ADHD plus anxiety. As a Texas PMHNP, you literally cannot prescribe these via telehealth — the supervising physician would need to handle it.

Florida’s twist: Florida limits NP prescribing of Schedule II to 7 days unless you’re a ‘psychiatric nurse’ treating a mental illness. Psychiatric NPs with proper certification get an exemption, meaning you can prescribe Schedule II psychiatric medications (stimulants, some sedatives) beyond 7 days when treating mental health conditions.

Good news: Most anxiety-specific medications are Schedule IV (benzodiazepines) or not controlled (SSRIs, SNRIs). NPs can prescribe these in all states with prescriptive authority.

Prescription Drug Monitoring Programs: The Daily Reality

Every state now has a PDMP (Prescription Drug Monitoring Program). When prescribing controlled substances — including benzodiazepines for anxiety — you’re required to check it. The details vary:

New York (Strictest): Check the I-STOP system before every Schedule II-IV prescription. Every single time. No exceptions unless system is down.

Pennsylvania: Check before initial prescription of any opioid or benzodiazepine, then for each subsequent prescription. This effectively means every time for these drug classes.

California: Check CURES database at least every 4 months for ongoing controlled substance therapy.

Florida: Check E-FORCSE before prescribing any Schedule II-V controlled substance and every 90 days for ongoing therapy.

Texas: Mandatory check for opioids, benzodiazepines, barbiturates, and carisoprodol before prescribing.

Illinois: Required for Schedule II; strongly encouraged for all controlled substances.

The workflow reality: Most modern EHR systems integrate PDMP checking, making this a 30-second task. But it’s legally required and audited. State boards do discipline providers for failing to check.

E-Prescribing: Almost Everywhere Now

California and New York mandate e-prescribing for all prescriptions, controlled or not. Most other states require it for controlled substances specifically.

Paper prescriptions for controlled substances are basically extinct in telehealth. You need:

• DEA-compliant EPCS (Electronic Prescribing of Controlled Substances) system
• Two-factor authentication
• Secure identity proofing

Telehealth platforms typically provide this infrastructure. If you’re solo, you’ll need to set it up through your EHR vendor.

State-Specific Prescribing Rules That Actually Affect Anxiety Treatment

California

• No state-mandated in-person exam for telehealth prescribing (as long as standard of care is met)
• Telehealth exam — even asynchronous intake forms combined with video — can establish patient relationship
• CURES PDMP check every 4 months for ongoing controlled Rx
• Not in IMLC (physicians need separate CA license)

Texas

• Audio-visual exam required for new patient evaluation
• Can prescribe anxiety meds including benzos via telehealth for mental health treatment
• Cannot use telehealth for chronic pain management with Schedule II (doesn’t affect anxiety treatment)
• PDMP mandatory for opioids, benzos, barbiturates before prescribing
• In IMLC (easier for out-of-state physicians)

Florida

• Schedule II via telehealth is banned EXCEPT for psychiatric treatment (plus inpatient, hospice, nursing home)
• This carve-out means psychiatrists and psych NPs can prescribe stimulants, etc., for mental health conditions
• Written patient consent for telehealth required
• E-FORCSE PDMP check before any controlled substance Rx and every 90 days
• Offers telehealth registration for out-of-state providers

New York

• No in-person exam requirement; telehealth evaluation acceptable
• I-STOP mandatory: check PMP for every Schedule II-IV prescription
• E-prescribing required for all medications (since 2016)
• Experienced NPs (3,600+ hours) have full practice authority
• Not in IMLC

Pennsylvania

• No specific teleprescribing restrictions in statute (follows federal rules)
• PDMP check required before initial prescription of any opioid or benzodiazepine and for each subsequent prescription
• NPs limited to 30-day supply of Schedule II, 90-day supply of Schedule III-IV
• Collaborative agreement required for NPs (no independence yet)
• In IMLC

Illinois

• Telehealth-friendly; no in-person exam mandate
• Audio-only telehealth permitted for mental health when necessary
• Full practice authority available for experienced NPs (4,000 hours)
• State controlled substance license required (in addition to DEA)
• PDMP required for Schedule II
• In IMLC

What These Regulations Mean for Your Practice Economics

Here’s what nobody talks about: compliance isn’t just about avoiding discipline — it’s a significant operational cost.

If you’re practicing in six states:

• Licensing fees: $4,000-5,000 initially, then $2,000-3,000 annually in renewals
• DEA registration: $888 every 3 years
• State controlled substance licenses: $100-300 per state
• Continuing education: Variable by state, but budget $500-1,000/year to stay current
• PDMP registration: Usually free but time to set up in each state
• EHR/EPCS costs: $100-400/month for compliant e-prescribing
• Malpractice insurance: Multi-state telehealth coverage runs $3,000-8,000/year

Administrative time: Tracking different state requirements, PDMP checks, documentation standards, and regulatory updates is easily 5-10 hours per month once you’re established across multiple states.

This is why many providers choose to work with platforms that handle compliance infrastructure. When Klarity Health manages licensing tracking, PDMP integration, and regulatory updates, you’re paying for that with your per-appointment fee — but you’re also not spending your clinical time navigating bureaucracy.

The Coming Changes: What to Watch in 2026

DEA Final Rule on Telemedicine: Expected sometime in 2026. Current speculation is they’ll allow some telemedicine prescribing of controlled substances but with requirements like:

• Special telemedicine DEA registration
• Possible in-person visit within a certain timeframe (30-180 days)
• Enhanced documentation requirements

State Legislation Trends:

• More states moving toward full practice authority for NPs (though it’s slow)
• Increasing PDMP integration requirements
• Potential restrictions on long-term benzodiazepine prescribing (guideline-driven, not necessarily law)

Practical advice: Don’t build your entire practice model around current temporary flexibilities. Have a contingency plan for when DEA rules tighten.

The Bottom Line for Anxiety Treatment Providers

Treating anxiety via telehealth in 2026 is legally viable and clinically appropriate. The regulatory complexity is real, but it’s navigable:

What’s working:

• Federal telehealth prescribing flexibilities extended (for now)
• Most states explicitly allow tele-mental health
• Insurance coverage is solid post-COVID
• Technology infrastructure (EHRs, e-prescribing, PDMPs) is mature

What’s complicated:

• Multi-state licensing is expensive and administrative
• NP scope varies wildly by state
• PDMP requirements differ everywhere
• Coming DEA rule changes create uncertainty

What platforms like Klarity Health solve:

• Multi-state licensing tracking and support
• Compliance infrastructure built in (PDMP integration, e-prescribing)
• Physician collaborators arranged in restricted-practice states
• Regulatory monitoring and updates
• Pre-qualified patient flow without marketing spend

Instead of spending $5,000 getting licensed in six states, setting up PDMP access everywhere, navigating collaborative agreements, AND figuring out patient acquisition, you pay per appointment and treat patients. The economics make sense when you price in the true cost of DIY compliance.

For most psychiatrists and PMHNPs, especially those building or scaling a practice, letting someone else handle the regulatory maze means you can focus on what you’re actually good at: treating anxiety disorders effectively.

FAQ

Can I prescribe benzodiazepines via telehealth in 2026?
Yes, under current federal rules (extended through at least December 31, 2025 and likely beyond). You can prescribe Schedule IV benzodiazepines after a proper telehealth evaluation without an in-person visit. However, you must comply with state PDMP checking requirements and e-prescribing mandates.

Do I need a separate license for every state where I treat patients?
Yes. You must hold a valid license in each state where your patient is physically located during the telehealth visit. The Interstate Medical Licensure Compact (IMLC) can expedite this for physicians in participating states. Florida offers a special telehealth registration as an alternative to full licensure.

What’s the difference between what psychiatrists and PMHNPs can prescribe for anxiety?
Psychiatrists have full prescribing authority in all states with no restrictions specific to anxiety medications. PMHNPs’ prescribing authority varies by state — from full independence in states like Illinois and New York (for experienced NPs) to requiring physician collaboration in Texas, Florida, and Pennsylvania. Notably, Texas restricts NP prescribing of Schedule II controlled substances to hospital/hospice settings only.

How often do I need to check the state prescription monitoring database?
It varies by state. New York requires checking before every Schedule II-IV prescription. Pennsylvania requires it before each opioid or benzodiazepine prescription. California requires at least every 4 months for ongoing controlled substance therapy. Florida requires initial check and every 90 days. Check your specific state’s requirements.

Can I use phone-only visits to prescribe anxiety medications?
Generally no, especially for controlled substances. Most states and current DEA guidance expect audio-visual (video) telehealth for establishing new patient relationships and prescribing controlled medications. Audio-only might be acceptable for established patient follow-ups in some states (like Illinois for mental health), but video is the safer standard.

What happens when DEA rules change in 2026?
The DEA is expected to finalize new telemedicine prescribing rules sometime in 2026. These will likely require some form of in-person evaluation (either initially or within a set timeframe) or a special telemedicine DEA registration. Providers should monitor DEA announcements and be prepared to adjust practice models accordingly.

Is treating anxiety patients in multiple states economically viable as a solo provider?
It depends on patient volume. Multi-state licensing costs $4,000-5,000 initially plus $2,000-3,000/year in renewals, plus administrative time. For most providers, especially those starting out, working with a platform that handles compliance infrastructure and provides patient flow is more economically efficient than building multi-state DIY capability while also funding patient acquisition.

References

1. Drug Enforcement Administration (DEA). ‘DEA and HHS Extend Telemedicine Flexibilities through 2025.’ Press Release, November 15, 2024. https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025

2. Center for Connected Health Policy. ‘State Telehealth Policies for Online Prescribing.’ Updated January 9, 2026. https://www.cchpca.org/topic/online-prescribing/

3. Florida Statutes § 456.47 (Telehealth Services) and § 464.012 (Advanced Practice Registered Nurses). 2025 edition. http://www.leg.state.fl.us/Statutes/

4. Texas Board of Nursing. ‘APRN Prescriptive Authority FAQ – Schedule II Prescribing.’ Updated December 9, 2025. https://www.bon.texas.gov/faqpracticeaprn.asp.html

5. New York Department of Health. ‘I-STOP/Prescription Monitoring Program Requirements.’ Effective August 27, 2013 (accessed 2025). https://health.ny.gov/professionals/narcotic/prescription_monitoring

Source:

• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=forward%20for%20telemedicine%2C%20DEA%20and,through%20the%20end%20of%202024
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Controlled%20Substance%20Act
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Note%20that%20the%20practice%20of,chapter%205%20of%20title%205
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,services%20within%20the%20applicable%20scope
• https://healthweb-back.health.ny.gov/professionals/narcotic/prescription_monitoring/#:~:text=Effective%20August%2027%2C%202013%2C%20most,to%20view%20dispensed%20controlled%20substance
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=may%20prescribe%20Schedule%20II%20drugs%3F,care%20from%20a%20qualified%20hospice
• https://www.leg.state.fl.us/Statutes/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=893.03%20to%20a%207,formulary%20which%20it%20finds%20is
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Additionally%2C%20the%20rule%20shall%20state,addiction%20medicine%2C%20or%20palliative%20care
• https://www.cchpca.org/topic/online-prescribing/#:~:text=The%20Attorney%20General%20may%20issue,application%20for%20such%20special%20registration%E2%80%94